{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:16:58Z","timestamp":1790835418188,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:00:00Z","timestamp":1426032000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s00213-015-3889-y","type":"journal-article","created":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T23:00:12Z","timestamp":1425942012000},"page":"2587-2595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia"],"prefix":"10.1007","volume":"232","author":[{"given":"Amir I. A.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke A. H.","family":"van den Elsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Colbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Kramers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein A.","family":"van der Marck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel G. M.","family":"Olde Rikkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,11]]},"reference":[{"key":"3889_CR1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.euroneuro.2014.06.007","volume":"24","author":"AI Ahmed","year":"2014","unstructured":"Ahmed AI, van den Elsen GA, Colbers A, van der Marck MA, Burger DM, Feuth TB, Olde Rikkert MG, Kramers C (2014a) Safety and pharmacokinetics of oral delta-9- tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. Eur Neuropsychopharmacol 24:1475\u20131482","journal-title":"Eur Neuropsychopharmacol"},{"key":"3889_CR2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/jgs.12661","volume":"62","author":"AI Ahmed","year":"2014","unstructured":"Ahmed AI, van den Elsen GA, van der Marck MA, Olde Rikkert MG (2014b) Medicinal use of cannabis and cannabinoids in older adults: where is the evidence? J Am Geriatr Soc 62:410\u2013411","journal-title":"J Am Geriatr Soc"},{"key":"3889_CR3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11136-012-0226-3","volume":"22","author":"AM Arons","year":"2013","unstructured":"Arons AM, Krabbe PF, van der Wilt GJ, Olde Rikkert MG, Adang EM (2013) Visual analogue scales: scale recalibration by patients with dementia and their proxies. Qual Life Res 22:979\u2013986","journal-title":"Qual Life Res"},{"key":"3889_CR4","first-page":"37","volume":"5","author":"E Aso","year":"2014","unstructured":"Aso E, Ferrer I (2014) Cannabinoids for treatment of Alzheimer\u2019s disease: moving toward the clinic. Front Pharmacol 5:37","journal-title":"Front Pharmacol"},{"key":"3889_CR5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-2012-111862","volume":"30","author":"E Aso","year":"2012","unstructured":"Aso E, Palomer E, Juv\u00e9s S, Maldonado R, Mu\u00f1oz FJ, Ferrer I (2012) CB1 agonist ACEA protects neurons and reduces the cognitive impairment of A\u03b2PP\/PS1 mice. J Alzheimers Dis 30:439\u2013459","journal-title":"J Alzheimers Dis"},{"key":"3889_CR6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(03)00381-8","volume":"2","author":"D Baker","year":"2003","unstructured":"Baker D, Pryce G, Giovannoni G, Thompson AJ (2003) The therapeutic potential of cannabis. Lancet Neurol 2:291\u2013298","journal-title":"Lancet Neurol"},{"key":"3889_CR7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00000542-199801000-00015","volume":"88","author":"TA Bowdle","year":"1998","unstructured":"Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88:82\u201388","journal-title":"Anesthesiology"},{"key":"3889_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.323.7303.13","volume":"323","author":"FA Campbell","year":"2001","unstructured":"Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13\u201316","journal-title":"BMJ"},{"key":"3889_CR9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","volume":"63","author":"CB Carroll","year":"2004","unstructured":"Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP (2004) Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63:1245\u20131250","journal-title":"Neurology"},{"key":"3889_CR10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/092986710790416326","volume":"17","author":"A Corsonello","year":"2010","unstructured":"Corsonello A, Pedone C, Incalzi RA (2010) Age related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 17:571\u2013584","journal-title":"Curr Med Chem"},{"key":"3889_CR11","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308\u20132314","journal-title":"Neurology"},{"key":"3889_CR12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","volume":"34","author":"WA Devane","year":"1988","unstructured":"Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605\u2013613","journal-title":"Mol Pharmacol"},{"key":"3889_CR13","unstructured":"Dronabinol. Dronabinol prescribing information. http:\/\/www.fda.gov\/ohrms\/dockets\/dockets\/05n0479\/05N-0479-emc0004-04.pdf . Accessed 1 Jul 2014"},{"key":"3889_CR14","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/jnr.23452","volume":"92","author":"M Fishbein-Kaminietsky","year":"2014","unstructured":"Fishbein-Kaminietsky M, Gafni M, Sarne Y (2014) Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage. J Neurosci Res 92:1669\u20131677","journal-title":"J Neurosci Res"},{"key":"3889_CR15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-91-6-825","volume":"91","author":"S Frytak","year":"1979","unstructured":"Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O\u2019Connell MJ, Schutt AJ, Schwartau NW (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy A comparison with prochlorperazine and a placebo. Ann Intern Med 91:825\u2013830","journal-title":"Ann Intern Med"},{"key":"3889_CR16","unstructured":"Guidance for Industry: Bioanalytical Method Validation US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) May 2001: http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070107.pdf Accessed 1 Jul 2014"},{"key":"3889_CR17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/187231212804096655","volume":"6","author":"M Joerger","year":"2012","unstructured":"Joerger M, Wilkins J, Fagagnini S, Baldinge R, Brenneisen R, Schneider U, Goldman B, Weber M (2012) Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metab Lett 6:102\u2013108","journal-title":"Drug Metab Lett"},{"key":"3889_CR18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2125.2012.04164.x","volume":"74","author":"LE Klumpers","year":"2012","unstructured":"Klumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM (2012) Novel Delta(9)-tetrahydrocannabinol formulation Namisol\u00ae has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 74:42\u201353","journal-title":"Br J Clin Pharmacol"},{"key":"3889_CR19","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1592\/phco.2005.25.10.1396","volume":"25","author":"SA Linnebur","year":"2005","unstructured":"Linnebur SA, O'Connell MB, Wessell AM, McCord AD, Kennedy DH, DeMaagd G, Dent LA, Splinter MY, Biery JC Jr, Chang F, Jackson RC, Miller SL, Sterling T, Force AT (2005) Pharmacy practice, research, education, and advocacy for older adults. Pharmacotherapy 25:1396\u20131430","journal-title":"Pharmacotherapy"},{"key":"3889_CR20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2125.2011.03970.x","volume":"72","author":"ME Lynch","year":"2011","unstructured":"Lynch ME, Campbell F (2011) Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72:735\u2013744","journal-title":"Br J Clin Pharmacol"},{"key":"3889_CR21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","volume":"346","author":"LA Matsuda","year":"1990","unstructured":"Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561\u2013564","journal-title":"Nature"},{"key":"3889_CR22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269","journal-title":"Alzheimers Dement"},{"key":"3889_CR23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","volume":"365","author":"S Munro","year":"1993","unstructured":"Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61\u201365","journal-title":"Nature"},{"issue":"Suppl 1","key":"3889_CR24","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","volume":"147","author":"RG Pertwee","year":"2006","unstructured":"Pertwee RG (2006) Cannabinoid pharmacology: the first 66\u00a0years. Br J Pharmacol 147(Suppl 1):S163\u2013S171","journal-title":"Br J Pharmacol"},{"key":"3889_CR25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International Union of Basic and Clinical Pharmacology LXXIX Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev 62:588\u2013631","journal-title":"Pharmacol Rev"},{"key":"3889_CR26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","volume":"43","author":"GC Rom\u00e1n","year":"1993","unstructured":"Rom\u00e1n GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A et al (1993) Vascular dementia: diagnostic criteria for research studies Report of the NINDS-AIREN International Workshop. Neurology 43:250\u2013260","journal-title":"Neurology"},{"key":"3889_CR27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJM198001173020302","volume":"302","author":"SE Sallan","year":"1980","unstructured":"Sallan SE, Cronin C, Zelen M, Zinberg NE (1980) Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 302:135\u2013138","journal-title":"N Engl J Med"},{"key":"3889_CR28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00228-012-1393-4","volume":"69","author":"CG Stott","year":"2013","unstructured":"Stott CG, White L, Wright S, Wilbraham D, Guy GW (2013) A phase I study to assess the effect of food on the single dose bioavailability of the THC\/CBD oromucosal spray. Eur J Clin Pharmacol 69:825\u2013834","journal-title":"Eur J Clin Pharmacol"},{"key":"3889_CR29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.arr.2014.01.007","volume":"14","author":"GA Elsen van den","year":"2014","unstructured":"van den Elsen GA, Ahmed AI, Lammers M, Kramers C, Verkes RJ, van der Marck MA, Rikkert MG (2014) Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res Rev 14:56\u201364","journal-title":"Ageing Res Rev"},{"key":"3889_CR30","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s11095-007-9291-7","volume":"24","author":"C Viswanathan","year":"2007","unstructured":"Viswanathan C, Bansal S, Booth B (2007) Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res 24:1962\u20131973","journal-title":"Pharm Res"},{"key":"3889_CR31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","volume":"12","author":"L Volicer","year":"1997","unstructured":"Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry 12:913\u2013919","journal-title":"Int J Geriatr Psychiatry"},{"key":"3889_CR32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","volume":"185","author":"S Walther","year":"2006","unstructured":"Walther S, Mahlberg R, Eichmann U, Kunz D (2006) Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology 185:524\u2013528","journal-title":"Psychopharmacology"},{"key":"3889_CR33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/JCP.0b013e31820e861c","volume":"31","author":"S Walther","year":"2011","unstructured":"Walther S, Schupbach B, Seifritz E, Homan P, Strik W (2011) Randomized, controlled crossover trial of dronabinol, 25\u00a0mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol 31:256\u2013258","journal-title":"J Clin Psychopharmacol"},{"key":"3889_CR34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jagp.2012.11.022","volume":"22","author":"MR Woodward","year":"2014","unstructured":"Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM (2014) Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry 22:415\u2013419","journal-title":"Am J Geriatr Psychiatry"},{"key":"3889_CR35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/0269881108089581","volume":"22","author":"L Zuurman","year":"2008","unstructured":"Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JC, Verpoorte R, Pinquier JL, Cohen AF, van Gerven JM (2008) Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol 22:707\u2013716","journal-title":"J Psychopharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-015-3889-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-015-3889-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-015-3889-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T16:31:10Z","timestamp":1747758670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-015-3889-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,11]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["3889"],"URL":"https:\/\/doi.org\/10.1007\/s00213-015-3889-y","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,11]]}}}